Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor

Clinical trial NCT07166315 · RECRUITING

Trial details

NCT number: NCT07166315
Sponsor: Adelphi Real World
Status: RECRUITING
Study type: OBSERVATIONAL

Axial Spondylarthritis (axSpA)Psoriatic Arthritis (PsA)

Start date: 2025-07-07
Primary completion: 2027-03-01
Enrollment: 700

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.